HHV-6, HHV-7, AND IMMUNOCOMPROMISED PATIENTS

HHV-6、HHV-7 和免疫功能低下的患者

• 批准号: 3148441
• 负责人: Paul D Griffiths
• 金额: $ 20.24万
• 依托单位: U OF L ROYAL FREE HOSPITAL SCH OF MED
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-07-15 至 1996-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3148441
• 关键词: AIDS; HIV infections; artificial immunosuppression; bone marrow transplantation; clinical chemistry; communicable disease transmission; cytomegalovirus; genetic strain; human herpesvirus 6; human subject; humoral immunity; kidney transplantation; liver transplantation; medical complication; opportunistic infections; pathologic process; serology /serodiagnosis; serotyping; transplantation; virulence; virus antigen; virus infection mechanism; virus replication

Two new human herpesviruses have recently been described. The overall objective of this project is to better define their medical significance in immunocompromised patients in whom other herpesviruses are important pathogens. Specific Aim 1 To collect serial samples from the patients and test for the presence of HHV6 and HHV7 using qualitative PCR, quantitative PCR and methods to type strains of virus. Specific Aim 2 To use these virologic criteria to define infected patients so that the specificity and sensitivity of serologic methods for IgG antibodies can be determined. Specific Aim 3 To analyse all of the results obtained to identify temporal associations between the presence of either virus and particular clinical syndromes. To determine if these syndromes are associated with greater amounts of virus detected by quantitative methods. To determine the prognostic value for future disease of detecting either virus qualitatively or quantitatively in a prospective manner. Specific Aim 4 To determine whether infection or disease attributable to either virus is acquired from endogeneous reactivation of virus or from primary infection or reinfection from the donor organ in patients undergoing transplant. To determine if pre-existing immunity in the recipient can moderate the pathologic potential of these viruses. Overall, this project will define the medical significance of these new human herpesviruses for immunocompromised patients and will define when virus replication is at its highest so that trials of antiviral chemotherapy can be planned.

最近描述了两种新的人类疱疹病毒。整体而言 这个项目的目的是更好地定义它们的医学意义 在免疫功能低下的患者中，其他疱疹病毒也很重要 病原体。 具体目标1 从病人身上采集系列样本并检测是否存在 用定性、定量聚合酶链式反应和分型方法检测HHV6和HHV7 病毒株。 具体目标2 使用这些病毒学标准来定义受感染的患者，以便 血清学方法检测免疫球蛋白抗体的特异性和敏感性 下定决心。 具体目标3 分析所有获得的结果以确定时间关联 任何一种病毒的存在与特定临床症状之间的关系。至 确定这些症状是否与更多的病毒有关 用定量的方法检测。以确定脑血管疾病的预后价值 对病毒进行定性或定量检测的未来疾病 以预期的方式。 具体目标4 以确定由任一病毒引起的感染或疾病是否 从内源性病毒再激活或从初次感染中获得 或在接受移植的患者中从供体器官再次感染。至 确定接受者中预先存在的豁免权是否可以缓和 这些病毒的病理潜在性。 总体而言，该项目将定义这些新的医疗意义 免疫受损患者的人类疱疹病毒，并将定义何时 病毒复制处于最高水平，因此抗病毒试验 化疗是可以计划的。